Impact of disease activity and treatment of comorbidities on the risk of
myocardial infarction in rheumatoid arthritis by Meissner, Yvette et al.
RESEARCH ARTICLE Open Access
Impact of disease activity and treatment of
comorbidities on the risk of myocardial
infarction in rheumatoid arthritis
Yvette Meissner1*, Angela Zink2, Jörn Kekow3, Karin Rockwitz4, Anke Liebhaber5, Silke Zinke6, Kerstin Gerhold1,
Adrian Richter1, Joachim Listing1 and Anja Strangfeld1
Abstract
Background: The aim was to estimate the impact of individual risk factors and treatment with various disease-
modifying antirheumatic drugs (DMARDs) on the incidence of myocardial infarction (MI) in patients with
rheumatoid arthritis (RA).
Methods: We analysed data from 11,285 patients with RA, enrolled in the prospective cohort study RABBIT, at the
start of biologic (b) or conventional synthetic (cs) DMARDs. A nested case–control study was conducted, defining
patients with MI during follow-up as cases. Cases were matched 1:1 to control patients based on age, sex, year of
enrolment and five cardiovascular (CV) comorbidities. Generalized linear models were applied (Poisson regression
with a random component, conditional logistic regression).
Results: In total, 112 patients developed an MI during follow-up. At baseline, during the first 6 months of follow-up
and prior to the MI, inflammation markers (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)) but
not 28-joint-count disease activity score (DAS28) were significantly higher in MI cases compared to matched
controls and the remaining cohort. Baseline treatment with DMARDs was similar across all groups. During follow-up
bDMARD treatment was significantly more often discontinued or switched in MI cases. CV comorbidities were
significantly less often treated in MI cases vs. matched controls (36 % vs. 17 %, p < 0.01). In the adjusted regression
model, we found a strong association between higher CRP and MI (OR for log-transformed CRP at follow-up: 1.47,
95 % CI 1.00; 2.16). Furthermore, treatment with prednisone ≥10 mg/day (OR 1.93, 95 % CI 0.57; 5.85), TNF inhibitors
(OR 0.91, 95 % CI 0.40; 2.10) or other bDMARDs (OR 0.85, 95 % CI 0.27; 2.72) was not associated with higher MI risk.
Conclusions: CRP was associated with risk of MI. Our results underline the importance of tight disease control
taking not only global disease activity, but also CRP as an individual marker into account. It seems irrelevant with
which class of (biologic or conventional) DMARD effective control of disease activity is achieved. However, in some
patients the available treatment options were insufficient or insufficiently used - regarding DMARDs to treat RA as
well as regarding the treatment of CV comorbidities.
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Background
In rheumatoid arthritis (RA), increased morbidity and
mortality due to myocardial infarctions (MI) cannot
entirely explained by traditional cardiovascular (CV)
risk factors [1–3]. There is evidence that the rheum-
atic disease itself contributes to the risk of CV events
[1, 4–6], with inflammation as the link between RA
and CV disease (CVD). Some of the pivotal pro-
inflammatory mediators, including the cytokines tumour
necrosis factor (TNF), interleukin 1 (IL-1) and interleukin
6 (IL-6) [7, 8], as well as the acute-phase reactant C-
reactive protein (CRP), are involved in atherogenesis and
eventually in the development of coronary artery diseases
like MI [9].
A recent meta-analysis of studies investigating single
nucleotide polymorphisms (SNPs) hypothesized a causal
role of the IL6R-gene signalling via the inflammatory
markers CRP and fibrinogen in the development of cor-
onary heart disease (CHD) [10]. The awareness of even
relatively low levels of CRP as a risk factor for MI has
increased in the rheumatologic community. A few stud-
ies of MI in RA examined prospectively collected CRP
[11–15]. Nevertheless, other studies have identified
erythrocyte sedimentation rate (ESR) as a relevant in-
flammation marker in CVD [16–19]. Similarly, high dis-
ease activity measured by the composite score based on
28 joints (DAS28) is discussed to have an important in-
fluence on the risk of MI [17, 19]. The European League
Against Rheumatism (EULAR) recommendations for CV
risk management require “adequate control of disease
activity” [20]. However, global disease activity might not
be sensitive enough in patients at increased risk of MI.
Therefore, the question remains whether CRP and/or
ESR should be taken into account as additional targets
in a treat-to-target approach. Randomised clinical trials
are unable to answer this question due to the long la-
tency to the outcome of MI, the restricted follow-up
time and the exclusion of patients with major CVD. Ob-
servational studies, on the other hand, should be suitable
to investigate risk factors for MI. However, comparisons
between patients with RA who develop MI and the rest
of the cohort are difficult to interpret in observational
studies, due to significant differences in age, sex and CV
comorbidities [12, 19].
To control for these confounding factors, a few studies
applied a matched case-control design [21, 22], but the
results are conflicting. Radovits et al. could neither con-
firm CRP nor DAS28 as risk factors for MI [22], whereas
Mantel et al. observed significantly elevated ESR, CRP
and DAS28 in cases compared to controls [21]. These
contradictory results may be caused by sparse matching
procedures: matching for disease duration only [22] and
matching for sex, year of RA diagnosis and rheumato-
logic unit [21].
We pursued two aims with this study: First, to show
the influence of risk factors, especially the effect of in-
flammation, on the incidence of MI in patients with RA.
Second, we were interested in the impact of treatment:
(1) the treatment of RA with disease-modifying anti-
rheumatic drugs (DMARDs) and concomitant glucocor-
ticoids and (2) the treatment of CV comorbidities. To
preclude distorting effects we applied a case–control
study with an extended matching algorithm comprising




Data from the German biologics register Rheumatoid
Arthritis: Observation of Biologic Therapy (RABBIT) were
used. RABBIT is an ongoing observational cohort study in
which patients are included at the start of treatment with
a biologic (b)DMARD or a conventional synthetic
(cs)DMARD after failure of at least one prior csDMARD
[23, 24]. In brief, once enrolled, patients stay in the cohort
for at least the next 5 (if possible, 10) years. At regular
predefined times (0, 3 and 6 months, and then every
6 months) rheumatologists complete assessment forms at
clinical routine visits capturing current clinical status,
treatment and all adverse events that have occurred since
the last follow-up. Additionally, weight, height as well as
existing comorbidities and their treatment are assessed at
baseline. At all follow-up visits patients report their global
health status using numerical rating scales and their dis-
ability by the Hannover Functional Status Questionnaire
(FFbH), in which 100 % indicates full functional capacity
[25]. Smoking habits are stated at baseline. The study
protocol of RABBIT was approved by the ethics commit-
tee of the Charité University Medicine Berlin.
Study design and matching algorithm
We performed a nested case–control analysis based on
exact matching where each case was randomly matched
to one control patient from the same original cohort.
Matching criteria were sex, age at baseline (±3 years)
and CV comorbidity at baseline (hypertension, CHD,
heart failure, prior cerebrovascular event and hyperlipo-
proteinaemia). To ensure similar availability of treatment
options for each case–control pair, the year of inclusion
into RABBIT (±2 years) was also added as matching cri-
teria. Eligible controls had to to be still under observa-
tion and without a CV event at follow-up prior to the
index date of the corresponding case (calendar date of
the MI).
Case definition
Cases were defined as patients observed in RABBIT with
an MI as the first CV event after enrolment up to
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October 2013. The case definition included the following
reported diagnoses: MI (acute, silent or not otherwise
specified), ST segment elevation MI, non ST segment
elevation MI and anterior or posterior wall infarction.
For all reported MIs supplemental information on clin-
ical symptoms, cardiac biomarkers, electrocardiographic
changes and imaging results were requested on stan-
dardized forms from the rheumatologist. If available,
hospital discharge letters and death certificates were
reviewed. Individual patients were eligible as a case if
their first ever MI had occurred prior to enrolment in
RABBIT. These events are possibly subsumed in the co-
morbidity defined as CHD.
Validation of cases and controls
In a subgroup of patients (MIs reported to RABBIT until
October 2011 and their matching controls, npairs = 75),
on-site visits were performed to revalidate CV events
and to verify the control status of the corresponding
controls. During these on-site visits, the entire patient
records or electronic patient files were reviewed. This
comprised inpatient and outpatient records, laboratory
results and hospital discharge letters. A CV event listed
in the patient record during follow-up, which had not
been previously reported to RABBIT, was considered as
an event for the analysis. If this event was an MI and
had occurred in a control patient, this patient was re-
categorized as a case patient and a new control patient
was matched for that case. After data collection in the
rheumatologic units, the diagnoses of all reviewed pa-
tients were validated in a blinded process by a physician
(KG) to verify the case and control status. Only con-
firmed events were included.
DMARD exposure and concomitant treatment
Data on DMARD treatment are captured in RABBIT at
every follow-up time point, and include agent, dose,
frequency of administration and start/stop-dates. Concomi-
tant treatment with oral glucocorticoids including dosage
in prednisone-equivalents, nonsteroidal anti-inflammatory
drugs (NSAIDs) and inhibitors of cyclooxygenase-2
(COX-2) are prospectively collected. In addition, rheuma-
tologists report comorbidities and their medical treatment
at baseline. Patients with hypertension, CHD, heart failure
or hyperlipoproteinaemia, but without respective treat-
ment, were labelled as having no CV treatment.
For the analysis, bDMARDs were categorized into (1)
TNF inhibitor (TNFi) (adalimumab, certolizumab, etaner-
cept, golimumab and infliximab), (2) other bDMARDs
(abatacept, anakinra, rituximab and tocilizumab) and (3)
csDMARDs. In groups (1) and (2) combination with
csDMARD treatment was possible; group (3) was exclu-
sively treated with one or more csDMARDs. We applied
two different definitions of bDMARD exposure: to examine
treatment changes in the use of bDMARDs and to deter-
mine length and frequency of bDMARD episodes we con-
sidered the first missed dose or the switch between
bDMARDs as discontinuation. In contrast, in the multivari-
able analysis of the influence of RA treatments on the risk
of MI we considered patients as being exposed to a certain
DMARD class or glucocorticoid if at least one dose of the
drug was prescribed within the last 6 months prior to the
MI/index date.
Statistical analysis
For baseline comparison of MI cases and the remainder of
the RABBIT cohort we used the t test and Chi-squared
test. Comparisons in the matched case–control design
were drawn using the paired t test or McNemar's test.
CRP, ESR and DAS28 were analysed at different times: at
baseline, within the first 6 months after enrolment and up
to 18 months before the MI/index date. Persistence with
enrolment therapy was investigated using Kaplan-Meier
estimates. In addition, we were interested in the cumula-
tive number of treatment changes (sequence of DMARD
episodes). The switch from a csDMARD to a bDMARD
or the reverse and any switch between bDMARDs were
counted as treatment changes and were used to calculate
treatment episodes. We assumed that the number of
switches follow a Poisson distribution and applied a gener-
alized linear mixed model with a random component for
the matched case–control design.
Multiple conditional logistic regression analysis was
applied to investigate the impact of risk factors on the
likelihood of developing an MI (cases vs. controls). The
regression model was additionally adjusted for non-
matching criteria: CRP, smoking, diabetes and insuffi-
cient treatment of underlying CVD. CRP was included
as reported values within 6 months prior to the MI/
index date (analysis I) and as the average of all reported
values from baseline until the MI/index (analysis II).
Due to the skewed distribution of CRP values, log-
transformed CRP values (logCRP) were calculated. A
sub-analysis was applied, excluding patients with a re-
ported CHD at baseline (Npairs for the analysis = 77).
The most frequently missing data among case–control
pairs were on patient-reported smoking status (25/224,
11.2 %) at baseline. In subsequent analyses these patients
were considered in a separate category (unknown smok-
ing status) and not excluded. Missing data on ESR (CRP)
were less frequent: 1.4 % (0 %) at baseline and during
follow-up 9.5 % (8.1 %) at most in case–control pairs. In
the 6 months prior to MI, values of CRP were not avail-
able for seven pairs (six (5.4 %) cases and one (0.9 %)
control). For the analysis of the course of disease activity
we applied multiple imputations (nImputation = 5) of miss-
ing values. In conditional logistic regression we consid-
ered only pairs with observed values of ESR (CRP).
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P values <0.05 were regarded as statistically significant
without adjustment for multiple testing in univariate
comparisons. The matching was applied using the R-
package Optmatch of the freely available software R
[26]. All other analyses were applied using the Statistical
Analysis System (SAS) version 9.4.
Results
Between 1 May 2001 and 31 October 2013, a total of
11,285 patients were enrolled into the RABBIT register
(Fig. 1). Within that period of time, rheumatologists re-
ported 115 MIs as a first CV event. Due to the exact
matching algorithm matching controls were not found
for four male cases (aged 62, 64, 68 and 76 years) with
heart failure as a comorbidity. They were matched to
controls with heart failure but were allowed to differ
from their corresponding case in no more than two co-
morbidities (differences in hypertension in one pair, in
CHD in two pairs, in previous cerebrovascular events in
two pairs and in hyperlipoproteinaemia in one pair). For
two further male MI cases no appropriate controls were
found, due to their comorbidity status. These two pa-
tients were excluded. Similarly, patients with non-
confirmed MI (n = 3) were excluded. During on-site
visits, patients with non-reported MI (n = 2) were identi-
fied and included with a matching control. In total 112
eligible case–control pairs remained for the analyses
(Fig. 1).
Characteristics of matched pairs and the remainder of the
cohort at baseline
Case–control pairs differed significantly from other pa-
tients in the RABBIT cohort in all matching parameters
except for previous cerebrovascular events. In addition,
cases differed from the cohort in most of the non-
matching criteria (Table 1). Cases had significantly
higher CRP, ESR and DAS28, and more impaired phys-
ical function (FFbH) and comorbidities (diabetes and
chronic lung or renal disease). Compared to the cohort,
MI cases were more often treated with oral glucocorti-
coids (93.6 % vs. 79.6 %, p < 0.01).
Fig. 1 Flow chart for patient selection. *Because two controls turned out to be cases, four new controls had to be found in the second
matching. MI myocardial infarction, CVD cardiovascular disease
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The enrolment therapies (TNFi, other bDMARDs or
csDMARDs) were similarly distributed between cases, controls
and the cohort, with 45.5 % of cases on TNFi, 21.4 % on other
bDMARDs and 33.1 % on csDMARDs; the corresponding
figures among controls were 42.9 %, 21.4 % and 35.7 %, and
among the cohort, 50.8 %, 16.2 % and 33.0 %, respectively.





Remainder of the cohorta
n = 11,059
Matching criteria
Sex, male 48 (42.9) 48 (42.9) 2536 (22.9)‡
Age, years, mean (SD) 63.7 (9.1) 63.7 (9.1) 55.9 (12.5)‡
Hypertension 67 (60.4) 68 (60.7) 4102 (37.1)‡
Coronary heart disease 28 (25.2) 26 (23.2) 622 (5.6)‡
Heart failure 7 (6.3) 7 (6.3) 242 (2.2)‡
Previous cerebrovascular event 0 (0) 2 (1.8) 146 (1.3)
Hyperlipoproteinemia 19 (17.1) 18 (16.1) 869 (7.9)‡
Time to MI/index date, month, mean (SD) 31.0 (24.9) 29.5 (23.9) NA
Unmatched criteria
Observation time, months, mean (SD) 52.6 (28.6) 60.2 (28.0)† 44.4 (32.7)‡
Disease duration, years, mean (SD) 11.4 (10.6) 11.4 (9.4) 10.0 (9.1)
Rheumatoid factor positive 83 (74.1) 85 (75.9) 7942 (72.1)
CRP, mg/L, mean (SD) 23.5 (27.0) 16.5 (22.1)† 18.4 (26.6)‡
ESR, mm/h, mean (SD) 39.2 (28.9) 30.7 (20.6)† 31.3 (23.0)‡
DAS28, mean (SD) 5.6 (1.3) 5.5 (1.3) 5.2 (1.3)‡
FFbH, mean (SD) 53.1 (24.8) 58.4 (23.3) 63.0 (23.3)‡
Smoking, current 25 (22.3) 19 (17.0) 2355 (21.3)
Smoking, former 35 (31.3) 24 (21.4) 2589 (23.4)
Smoking, never 35 (31.3) 61 (54.5) 4698 (42.5)
Smoking, unknown 17 (15.2) 8 (7.1) 1417 (12.8)
BMI, mean (SD) 28.1 (5.6) 26.7 (4.0)† 26.6 (5.3)‡
BMI ≥30 kg/m2 34 (30.4) 19 (17.0)† 2514 (22.7)
Diabetes mellitus 26 (23.4) 14 (12.5)† 1075 (9.7)‡
Chronic renal disease 11 (9.9) 8 (7.1) 397 (3.6)‡
COPD 12 (10.8) 13 (11.6) 495 (4.5)‡
No. of previous csDMARDs, mean (SD) 2.6 (1.4) 2.8 (1.5) 2.4 (1.3)
No. of previous bDMARDs, mean (SD) 0.5 (1.0) 0.4 (0.9) 0.3 (0.7)
Oral glucocorticoids 103 (93.6) 87 (77.7)† 8788 (79.6)‡
Glucocorticoids, <5 mg/day 12 (10.9) 29 (25.9) 2981 (27.0)
Glucocorticoids, 5–10 mg/day 64 (58.2) 46 (41.1) 4997 (45.3)‡
Glucocorticoids, ≥10 mg/day 34 (30.9) 37 (33.0) 3048 (27.6)‡
Non-selective NSAIDs 47 (42.0) 39 (34.8) 4260 (38.5)
COX-2 inhibitors 17 (15.2) 23 (20.5) 1699 (15.4)
Any NSAIDs 62 (55.4) 62 (55.4) 5895 (53.3)
No CV treatmentb 27/75 (36.0) 13/75 (17.3)† 967/4584 (21.1)‡
Values are numbers of patients (%) unless otherwise specified. aPatients without myocardial infarction (MI) at follow-up and patients who were not matched
controls. bNo cardiovascular (CV) treatment: one or more of the reported cardiovascular disease (CVD) at baseline (hypertension, coronary heart disease, heart
failure or hyperlipoproteinaemia) is not reported as being treated
BMI body mass index, SD standard deviation, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score based on 28 joints, FFbH
Hannover Functional Status Questionnaire, COPD chronic obstructive pulmonary disease, csDMARD conventional synthetic disease-modifying antirheumatic drug,
bDMARD biologic DMARD, NSAID nonsteroidal anti-inflammatory drug, COX-2 cyclooxygenase-2, NA not applicable. †P < 0.05 for comparison with cases (paired t
test or Mc Nemar´s test). ‡P < 0.05 for comparison with cases (unpaired t test or chi-squared test)
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Despite good agreement in the matching criteria, there
were significant differences between cases and controls
in CRP and ESR, obesity (body mass index (BMI)
≥30 kg/m2), diabetes and use of glucocorticoids. Import-
antly, among 75 case–control pairs with at least one
baseline CV comorbidity, those patients who developed
an MI during follow-up (cases) were significantly less
likely to receive medical treatment for their CV comor-
bidity than their corresponding controls (36 % vs. 17 %,
p < 0.01, Table 1).
Treatment with DMARDs during follow-up
The number of different DMARD episodes was signifi-
cantly higher in patients with MI than in matched con-
trols, with one episode in 51 cases (45.5 %), two
episodes in 30 cases (26.8 %) and ≥3 episodes in 31 cases
(27.7 %); in controls the corresponding figures were 77
(68.8 %), 19 (16.9 %) and 16 (14.3 %), respectively (p <
0.01, paired t test).
Persistence with bDMARD enrolment therapy was sig-
nificantly lower in cases compared to controls (p < 0.01,
log rank test). In 50 pairs who started simultaneously
with a bDMARD, 54.9 % (95 % CI 38.5; 68.5) of the
cases compared to 76.5 % (95 % CI 60.4; 86.7) of the
controls were still on the enrolment therapy at month 12.
In addition, prior to the MI/index date the number of
treatment switches (between different DMARDs) was
about 53 % higher in cases (Poisson regression 1.53, 95 %
CI 1.04; 2.27) than in respective controls. The median
duration of a DMARD episode was 7 months in cases
(IQR 4–17) and 13 months in controls (IQR 6–23).
Disease activity and inflammation during follow-up
During the first 6 months from baseline, the inflamma-
tion markers CRP and ESR were significantly elevated in
MI cases (Fig. 2, left; Table 2). In contrast, matched
controls achieved similar improvements to the rest of
the cohort (Table 2).
Fig. 2 Development of mean C-reactive protein (CRP, mg/L), mean erythrocyte sedimentation rate (ESR, mm/h) and mean disease
activity score based on 28 joints (DAS28) (all presented with error bars) at baseline, month 3 and month 6 in cases, matched controls
and the remainder of the RABBIT cohort (left) and 18 months prior to the myocardial infarction (MI)/index date in cases and matched
controls (right)
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The distinct differences between cases and controls
were still observed during the last 6 months (Table 3)
and the last 18 months prior to the MI/index date (Fig. 2,
right). Notably, no differences were found in DAS28.
The exclusion of patients with underlying CHD at
baseline did not alter the course of inflammation and
disease activity (Additional file 1).
Evaluation of risk factors for MI
In the univariate logistic comparison of cases and controls
there was an increased risk of MI with an increase of CRP
per 5 mg/L (OR 1.13 (95 % CI 1.02; 1.22) based on values
obtained within 6 months prior to the MI/index date). The
association with risk of MI was stronger with log-
transformed CRP (1.75 (1.24; 2.46)). Similarly, averaged and
log-transformed CRP over the total observation time was
significantly associated with risk of MI (1.75 (1.26; 2.43)).
Other significant predictors were absence of baseline CV
treatment (3.60 (1.28; 12.40)) and glucocorticoids at a
dosage of 5–10 mg/day (1.97 (0.98; 4.11) and ≥10 mg/day
(3.02 (1.11; 8.25) vs. glucocorticoids <5 mg/day). Previous
or current smoking (3.15 (1.47; 7.34)) and unknown smok-
ing status (2.68 (1.06; 7.30)) were significant risk factors
compared to not smoking. There was no significant associ-
ation between increased risk of MI and TNFi or other
bDMARD treatment (reference csDMARDs). The adjusted
multiple conditional logistic regression revealed no asso-
ciation between risk of MI and treatment with TNFi or
other bDMARDs, and no significantly higher risk with
glucocorticoid treatment of 5–10 mg/day or ≥10 mg/day
(Table 4). There was a strong association between log CRP
and MI, but not between raw CRP values and MI, confirm-
ing the expected non-linear association. Smoking was
confirmed as another significant risk factor.
The risk imposed by elevated CRP remained in a sub-
analysis of patients without CHD at baseline, although
this was no longer statistically significant for values
averaged over the complete observation period (until the
MI/index date).
Discussion
We investigated the risk of MI in a large observational
cohort study of 11,285 patients with established RA. An
in-depth comparison of patients who developed MI with
the remaining cohort revealed wide-ranging differences in
patient characteristics and exemplified the need for an
Table 2 Development of inflammation and disease activity in cases, controls and the remainder of the RABBIT cohort stratified by
enrolment therapy
Treatment at baseline Number Mean at baseline (95 % CI) Mean at month 3 (95 % CI) Mean at month 6 (95 % CI)
CRP (mg/L)
Cases csDMARD 37 21.6 (12.4; 30.8) 16.3 (9.0; 23.6) 14.3 (7.3; 21.2)
bDMARD 75 24.4 (18.2; 30.6) 19.5 (14.5; 24.5) 19.4 (13.5; 25.4)
Controls csDMARD 40 10.2 (6.1; 14.3) 9.8 (5.1; 14.5) 8.0 (4.7; 11.3)
bDMARD 72 20.0 (14.1; 25.9) 11.4 (7.4; 15.4) 11.0 (6.9; 15.0)
Cohort remainder csDMARD 3656 14.1 (13.5; 14.8) 11.4 (10.8; 11.9) 11.0 (10.4; 11.5)
bDMARD 7403 20.75 (20.1; 21.4) 12.9 (12.4; 13.3) 12.7 (12.2; 13.1)
ESR (mm/h)
Cases csDMARD 37 30.4 (23.9; 36.9) 27.7 (20.9; 34.5) 31.4 (23.8; 39.0)
bDMARD 75 43.2 (35.9; 50.4) 36.8 (30.5; 43.2) 34.7 (28.7; 40.7)
Controls csDMARD 40 26.8 (20.2; 33.4) 22.4 (16.5; 28.2) 19.4 (13.1; 25.7)
bDMARD 72 32.8 (28.1; 37.5) 22.7 (18.4; 27.1) 22.6 (18.8; 26.4)
Cohort remainder csDMARD 3656 27.4 (26.7; 28.0) 23.9 (23.3; 24.5) 23.5 (22.8; 24.2)
bDMARD 7403 33.3 (32.7; 33.8) 24.4 (24.0; 24.9) 24.4 (24.0; 25.0)
DAS28
Cases csDMARD 37 5.2 (4.8; 5.5) 4.0 (3.5; 4.4) 3.9 (3.4; 4.3)
bDMARD 75 5.8 (5.5; 6.1) 4.6 (4.2; 5.0) 4.6 (4.2; 5.0)
Controls csDMARD 40 4.8 (4.4; 5.3) 4.0 (3.6; 4.5) 3.5 (3.0; 4.0)
bDMARD 72 5.9 (5.6; 6.1) 4.1 (3.7; 4.4) 3.9 (3.6; 4.3)
Cohort remainder csDMARD 3656 4.8 (4.7; 4.8) 3.8 (3.7; 3.8) 3.7 (3.6; 3.7)
bDMARD 7403 5.4 (5.4; 5.5) 4.0 (3.9; 4.0) 3.9 (3.8; 3.9)
Mean values are averaged over five imputations and CI were corrected for the imputation variance
CI confidence interval, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score based on 28 joints, bDMARD biologic disease-modifying
antirheumatic drug, csDMARD conventional synthetic DMARD
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CRP, mg/L, mean (SD) 17.6 (25.0) 10.4 (14.6) 0.011
ESR, mm/h, mean (SD) 36.1 (26.5) 22.6 (16.2) <0.001
DAS28, mean (SD) 4.3 (1.4) 4.0 (1.5) 0.22
Tender joint count, mean (SD) 4.2 (5.0) 4.4 (5.6) 0.71
Swollen joint count, mean (SD) 3.8 (5.0) 4.6 (5.4) 0.17
NRS patient global health 0–10, mean (SD) 5.1 (2.2) 4.9 (2.0) 0.41
FFbH, mean (SD) 58.7 (27.1) 61.0 (24.2) 0.32
TNFi 50 (47.6 %) 55 (52.4 %) 0.41
Other bDMARDs 21 (20.0 %) 23 (21.9 %) 0.66
csDMARDs only 33 (31.4 %) 23 (21.9 %) 0.11
Glucocorticoids, <5 mg/day 44 (41.9 %) 62 (59.6 %)
Glucocorticoids, 5–10 mg/day 45 (42.9 %) 34 (32.7 %) 0.008
Glucocorticoids, ≥10 mg/day 16 (15.2 %) 8 (7.7 %)
Non-selective NSAIDs 60 (57.1 %) 62 (59.0 %) 0.77
COX-2 inhibitors 28 (26.7 %) 36 (34.3 %) 0.19
Any NSAID 72 (68.6 %) 78 (74.3 %) 0.33
Case–control pairs with missing C-reactive protein (CRP) values were not included in this analysis. Data represent averages of all reported values within 6 months
before the myocardial infarction (MI)/index date. All values are numbers of patients (%) unless otherwise specified. Tumour necrosis factor inhibitors (TNFi), other
biologic disease-modifying antirheumatic drugs (bDMARDs) and conventional synthetic DMARDS (csDMARDs) were counted if the patient received at least one
dose of the drug within 6 months before the MI/index date. For nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors, data
represent use in the 24 months before the MI/index date
SD standard deviation, ESR erythrocyte sedimentation rate, DAS28 disease activity score based on 28 joints, NRS numeric rating scale, FFbH Hannover Functional
Status Questionnaire
Table 4 Multivariate odds ratios for the risk of MI in the nested case–control analysis
All matched case–control pairs Subset of cases and controls without CHD
I II I II
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
Log CRP, prior MIa 1.58 (1.07; 2.33) 1.60 (1.04; 2.46)
Log CRP, total observationa 1.47 (1.00; 2.16) 1.44 (0.94; 2.19)
csDMARDs only Ref. Ref. Ref. Ref.
TNFi 0.96 (0.41; 2.22) 0.91 (0.40; 2.10) 1.24 (0.49; 3.16) 1.22 (0.49; 3.05)
Other bDMARDs 1.13 (0.34; 3.71) 0.85 (0.27; 2.72) 0.86 (0.19; 3.84) 0.53 (0.13; 2.18)
Glucocorticoids <5 mg/day Ref. Ref. Ref. Ref.
5–10 mg/day 1.33 (0.61; 2.89) 1.22 (0.56; 2.68) 1.42 (0.59; 3.43) 1.32 (0.55; 3.17)
≥10 mg/day 2.17 (0.69; 6.81) 1.83 (0.57; 5.85) 2.48 (0.72; 8.59) 2.18 (0.61; 7.79)
No CV treatmentb 2.76 (0.91; 8.32) 2.66 (0.88; 8.00) 2.42 (0.55; 10.77) 2.66 (0.60; 11.72)
Smoking never Ref. Ref. Ref. Ref.
Smoking ever 3.33 (1.45; 7.63) 2.93 (1.29; 6.66) 2.13 (0.85; 5.32) 2.03 (0.69; 5.93)
Smoking status unknown 2.15 (0.82; 5.66) 2.12 (0.80; 5.65) 1.74 (0.62; 4.88) 1.84 (0.65; 5.21)
Diabetes 2.08 (0.84; 5.18) 2.32 (0.94; 5.71) 1.95 (0.68; 5.63) 1.92 (0.67; 5.51)
Case–control pairs with missing C-reactive protein (CRP) values were not considered in this analysis. aAll CRP values were log-transformed. Analysis I: CRP values of the last
6 months prior to the myocardial infarction (MI)/index date, Analysis II: averaged CRP values from baseline until the MI/index date. bNo CV treatment: one or more of the
types of reported cardiovascular disease (CVD) at baseline (hypertension, coronary heart disease, heart failure and hyperlipoproteinaemia) is not reported as being treated.
Baseline information was used for no CV treatment, smoking and diabetes. All other treatments are values within 6 months before the MI/index date
OR odds ratio, CI confidence interval, CHD coronary heart disease, bDMARD biologic disease-modifying anti-rheumatic drug, csDMARD conventional synthetic
DMARD, TNFi tumour necrosis factor inhibitor
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appropriate study design beyond covariate adjustment. To
account for these differences we applied a nested case–
control design using an extensive matching algorithm that
enabled us to link homogeneous case–control pairs.
In a setting that controlled for traditional risk factors,
we found that inflammation and smoking were signifi-
cantly associated with the risk of MI in patients with
RA. At baseline, during the first 6 months of follow-up
and, more importantly, prior to the MI/index date
(Fig. 2), there was a distinct difference in CRP and ESR
levels between cases and controls. The significant differ-
ences in CRP values remained throughout the period of
observation. This result confirms recent findings of
others who report that the risk of MI is highest for pa-
tients with RA who have high CRP [15]. Similar to the
results of the Emerging Risk Factors Collaboration [27],
our data suggest a nonlinear increase in risk of MI with
rising CRP. Compared with the significantly increased
risk of MI with high sensitivity CRP values above 1 mg/L
among the general population [28], our data suggest that
the complete suppression of systemic inflammation in RA
may reduce the risk of MI.
Others have reported lower risk of MI in TNFi re-
sponders vs. TNFi non-responders [29, 30]. However,
based on the DAS28, patients can respond even when
CRP remains high [31], which is in line with our data.
Patients with MI presented with similar values of the
DAS28 prior to the MI/index date compared to control
patients, but with significantly elevated CRP and ESR.
We conclude that the evaluation of RA disease activity
solely based on the DAS28 may not be sufficient to pre-
dict risk of MI. The assessment should also comprise
the inflammatory marker CRP, particularly in patients
with present CVD or at increased risk of CVD.
We identified comparable treatment with DMARDs in
patients who developed MI and in the matched controls
at baseline only. During follow-up there were significant
differences: rheumatologists switched the bDMARD
treatment in cases significantly more often than in re-
spective controls, which indicates continuous attempts
to adapt the DMARD treatment. Nevertheless, switches
remained ineffective in reducing CRP (Fig. 2). This result
suggests that the available RA treatment options for
these patients were insufficient. New biologic drugs with
alternative targets have been available since 2007. A re-
cent meta-analysis discussed IL-6 inhibition as a possible
treatment target to prevent CVD [10]. This may be
appropriate for patients not responding to other
bDMARDs and with high average CRP. Due to the small
number of tocilizumab episodes (13 of 242 cases (5.4 %)
and 9 of 184 controls (4.9 %)), we could not study the
impact of this treatment separately.
There are conflicting results from previous studies re-
garding the influence of glucocorticoid treatment on the
risk of CVD. Some studies report a risk associated with
higher doses of glucocorticoids [32–36]. As expected, in
the univariate analysis we observed stronger association
between prednisone dose and MI risk than in the multi-
variate analyses after adjustment for average CRP. These
results suggest that the harmful effects of glucocorti-
coids reported by others are likely partly a result of pa-
tient channelling: patients who did not respond to the
primary treatment with bDMARDs were consequently
treated with glucocorticoids in higher doses. In this mat-
ter, concomitant glucocorticoids were used by rheuma-
tologists as a kind of rescue therapy. We observed that
the risk remained with glucocorticoid use ≥10 mg/day,
but this was not statistically significant and needs to be
investigated further in studies with sample sizes larger
than ours.
An obvious but rather unexpected risk factor was de-
tected in our data: in patients with a future MI, pre-
existing CV comorbidities were less frequently treated
than in the corresponding control patients. This suggests
that insufficient consideration of CV risk in patients
with known CV comorbidities is a further risk factor for
MI. There seems to be a gap between the knowledge
about CV risk in RA, respective recommendations [20,
37] and the daily management of patients. Our findings
confirm suboptimal risk management of CVD [38, 39].
One of the weaknesses of this study is the uncertainty
about the first-ever MI. In some of the patients the in-
formation about the first MI was subsumed in the co-
morbidity of CHD at baseline. Therefore, we performed
a sub-analysis in patients without reported CHD at base-
line. We calculated consistent estimates. A strength of
this study is the comprehensive on-site validation
process, which revealed low numbers of underreported
MI in patients with elevated risk of a CV event. How-
ever, on-site validation was stopped after reviewing 75
case–control pairs, as very little additional information
was obtained on laboratory parameters or CV treatment.
The size of the nested case–control study was too small
to estimate the separate effects of abatacept, rituximab
and tocilizumab [40, 41], or those of methotrexate, leflu-
nomide or other csDMARDs. The total amount of
missing data during follow-up was low (<10 %). Never-
theless, we applied multiple imputations but the impact
on estimates was statistically and clinically insignificant
when compared to an analysis of pairs with observed
data only.
Conclusion
In conclusion, our results underline the importance of a
treat-to-target approach, which has to take the global
disease activity and CRP into account. As inflammation is
the link to CVD, we consider CRP the most reliable
marker to assess the risk of MI. For many patients it
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seems less important by which DMARD treatment
(TNFi, other bDMARD or csDMARD) the treatment
target is reached. In some patients however, the avail-
able treatment options were insufficient or insuffi-
ciently used. This adds to the evidence indicating the
necessity of tight disease control and adequate treat-
ment of comorbidities.
Additional file
Additional file 1: Figure S1. Course of RA disease represented by CRP,
ESR and DAS28, and restricted to patients without coronary heart disease
at baseline. (DOCX 128 kb)
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